Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis KEEPsAKE 1&2 - RZB v PBO 1407 pts -baseline 63% enth, 28% dact, 20% both Wk 24: 14% decr. enthesitis, 17% decr dact, 13% decr both Mean time to resolution decreased Results maintained through wk 52 @RheumNow https://t.co/RBubeuJoh8